Injection intervals in treatment-naive neovascular age-related macular degeneration (nAMD) patients who received afibercept or ranibizumab: Intelligent Research in Sight (IRIS®) Registry analysis
Authors: MacCumber M, Yu JS, Sagkriotis A, Guruprasad B, Burugapalli B, Bi X, Cantrell RA, Agashivala N, Wykoff CC
October 2019
Back